Anto
Anto offers a computational platform that converts massive, noisy gut microbiome sequencing data into actionable causal signals for drug development. Using quality‑aware sparsification and causal modeling, it predicts drug toxicity and efficacy across diverse microbiome profiles and enables inverse design of microbial therapies, helping pharmaceutical R&D teams incorporate microbiome insights into discovery and safety assessment.
- Artificial Intelligence
- Data & Analytics
- Biotechnology
Funding
Raised to date
$500KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Drug development often overlooks the gut microbiome, treating it as background noise despite its significant impact on drug metabolism, efficacy, and toxicity. This omission leads to costly trial failures and adverse patient reactions because microbial variability across populations is not accounted for.
Solution
Anto provides a computational platform that transforms massive, noisy microbiome sequencing data into actionable causal signals for drug development. By applying quality-aware, goal-directed sparsification algorithms, the platform isolates the ~1% of microbiome data that carries predictive power, making the microbiome computationally tractable. It builds causal models of microbial ecosystems to forecast dynamics, predict counterfactual outcomes of interventions, and enable inverse design of microbial therapies. Integrated with large-scale multi-omics and over 100,000 interventional trajectories, Anto’s AI-guided lab‑in‑the‑loop validation links observational data to actionable interventions. The resulting Darwin model series predicts drug toxicity and efficacy across diverse populations, allowing pharmaceutical teams to optimize molecules for broader, microbiome‑aware efficacy.
Target Audience
Primary customers are pharmaceutical R&D teams and biotech companies seeking to incorporate microbiome considerations into drug discovery, safety assessment, and precision medicine pipelines.
Features
- Quality-aware sparsification algorithms that filter out ~99% noise from microbiome sequencing data
- Causal modeling of microbial ecosystems to forecast dynamics and simulate intervention outcomes
- AI‑guided lab‑in‑the‑loop validation using extensive multi‑omics and interventional trajectory datasets
- Darwin model suite for predicting drug toxicity and efficacy across heterogeneous microbiome profiles
- Capability to inverse‑design microbial therapies that modulate drug response
- Scalable computational pipeline that converts petabases of sequence data into usable causal insights